CR10431A - Sales y modificaciones del cristal de las mismas - Google Patents

Sales y modificaciones del cristal de las mismas

Info

Publication number
CR10431A
CR10431A CR10431A CR10431A CR10431A CR 10431 A CR10431 A CR 10431A CR 10431 A CR10431 A CR 10431A CR 10431 A CR10431 A CR 10431A CR 10431 A CR10431 A CR 10431A
Authority
CR
Costa Rica
Prior art keywords
salts
crystal
modifications
same
phenyl
Prior art date
Application number
CR10431A
Other languages
English (en)
Inventor
Lili Feng
Xinglong Jiang
Piotr Karpinski
Elizabeth A Hanley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10431A publication Critical patent/CR10431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a sales de 1-(2-fluoro-fenil)-3-(2-oxo-5-fenil-2,3-dihidro-1H-benzo[e]-[1,4]-diazepin-3-il)-urea, y a las formas cristalinas de las mismas, a su produccion y uso, y a preparaciones farmaceuticas que contienen estas sales y formas cristalinas.
CR10431A 2006-05-23 2008-11-10 Sales y modificaciones del cristal de las mismas CR10431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80283606P 2006-05-23 2006-05-23

Publications (1)

Publication Number Publication Date
CR10431A true CR10431A (es) 2009-01-07

Family

ID=38704747

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10431A CR10431A (es) 2006-05-23 2008-11-10 Sales y modificaciones del cristal de las mismas

Country Status (28)

Country Link
US (1) US7977330B2 (es)
EP (1) EP2029556B1 (es)
JP (2) JP2009538330A (es)
KR (1) KR20090009898A (es)
CN (1) CN101448796B (es)
AR (1) AR061056A1 (es)
AT (1) ATE486858T1 (es)
AU (1) AU2007267671A1 (es)
BR (1) BRPI0712556A2 (es)
CA (1) CA2650514A1 (es)
CL (1) CL2007001454A1 (es)
CR (1) CR10431A (es)
DE (1) DE602007010286D1 (es)
EC (1) ECSP088900A (es)
ES (1) ES2355166T3 (es)
GT (1) GT200800253A (es)
IL (1) IL195008A0 (es)
MA (1) MA30482B1 (es)
MX (1) MX2008014836A (es)
NO (1) NO20085000L (es)
PE (1) PE20080261A1 (es)
PL (1) PL2029556T3 (es)
PT (1) PT2029556E (es)
RU (1) RU2008150627A (es)
TN (1) TNSN08477A1 (es)
TW (1) TW200815375A (es)
WO (1) WO2007140154A2 (es)
ZA (1) ZA200809096B (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002871A (es) 2002-09-20 2005-10-05 Arrow Therapeutics Ltd Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.

Also Published As

Publication number Publication date
US20090163478A1 (en) 2009-06-25
US7977330B2 (en) 2011-07-12
WO2007140154A2 (en) 2007-12-06
MX2008014836A (es) 2008-12-01
PE20080261A1 (es) 2008-04-18
ECSP088900A (es) 2008-12-30
IL195008A0 (en) 2009-08-03
EP2029556B1 (en) 2010-11-03
MA30482B1 (fr) 2009-06-01
AR061056A1 (es) 2008-07-30
PL2029556T3 (pl) 2011-04-29
CL2007001454A1 (es) 2008-05-16
RU2008150627A (ru) 2010-06-27
BRPI0712556A2 (pt) 2013-07-02
JP2013075910A (ja) 2013-04-25
KR20090009898A (ko) 2009-01-23
ATE486858T1 (de) 2010-11-15
AU2007267671A1 (en) 2007-12-06
TNSN08477A1 (en) 2010-04-14
JP2009538330A (ja) 2009-11-05
DE602007010286D1 (de) 2010-12-16
ES2355166T3 (es) 2011-03-23
PT2029556E (pt) 2011-01-31
CN101448796B (zh) 2012-09-26
TW200815375A (en) 2008-04-01
GT200800253A (es) 2009-04-29
NO20085000L (no) 2008-12-23
WO2007140154A3 (en) 2008-03-20
EP2029556A2 (en) 2009-03-04
ZA200809096B (en) 2009-11-25
CN101448796A (zh) 2009-06-03
CA2650514A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY31471A1 (es) Derivados bis-(sulfonilamino) en terapia 066
UY30327A1 (es) Nuevos compuestos ii
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
AR054846A1 (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
NI200800020A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
ECSP088549A (es) Nuevos derivados de pirrol fusionado
ECSP078030A (es) Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona
CR10148A (es) Derivados de las benzamidas y heteroarenos
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
NI200800217A (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos.
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
UY30289A1 (es) Derivados de la 1h-pirrol-3-carboxamida sustituida con 1-(tetrahidro-2h-piran-4-il-metil)-1h-bencimidazol, composiciones conteniéndolos, procedimientos de preparacion y aplicaciones
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
UY27410A1 (es) Formas novedosas crudas cristalinas
ECSP088603A (es) Nuevas n-(fluor-pirazinil)-fenilsulfonamidas como moduladores del receptor de quimioquina ccr4
UY28835A1 (es) Nuevos derivados de la pirrolo (2, 3-b) piridina, su preparación y su utilización farmcéutica como inhibidores de cinasas.
DOP2006000248A (es) Acido 1-(1-(2-etoxietil)-3-etil-7-(4-metilpiridin-2-ilamino)-1h- pirazolo[4,3-d]pirimidin-5-il)piperidina-4-carboxílico y las sales del mismo.
UY29447A1 (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)